LLY vs NVO Comparison: AI Score, Valuation, Performance and Upside
LLY holds the edge across 3 of 5 key metrics in this comparison. LLY has delivered stronger 1-year price return (+54.91% vs -31.94%), though NVO has the better forward P/E setup (1.83x vs 24.87x for LLY). LLY leads on both revenue growth (47.70%) and operating margin (54.22%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for NVO (+17.55%) than for LLY (+11.96%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | LLY | NVO |
|---|---|---|
| AI scorei | 76.4 | 40.1 |
| AI ranki | #20 | #1088 |
| Latest closei | $1,164.89 | $39.80 |
| 1M returni | -7.21% | -14.85% |
| 6M returni | +27.93% | +13.49% |
| 1Y returni | +54.91% | -31.94% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | LLY | NVO |
|---|---|---|
| 1Y ago | $15.43K (+54.3%) started 2025-09-22 | $7.23K (-27.7%) started 2025-09-22 |
| 5Y ago | $54.04K (+440.4%) started 2021-09-23 | $9.88K (-1.2%) started 2021-09-21 |
| 10Y ago | $195.14K (+1851.4%) started 2016-09-23 | $28.31K (+183.1%) started 2016-09-21 |
Hypothetical — past performance does not guarantee future results.
| Metric | LLY | NVO |
|---|---|---|
| Market capi | $1.05T | $175.79B |
| Trailing P/Ei | 39.36 | 9.88 |
| Forward P/Ei | 24.87 | 1.83 |
| Price/Salesi | 14.10 | 0.53 |
| EV/Revenuei | 13.72 | 0.82 |
| Analyst targeti | $1,315.04 | $46.78 |
| Target upsidei | +11.96% | +17.55% |
| Metric | LLY | NVO |
|---|---|---|
| Revenue growthi | 47.70% | 2.10% |
| Earnings growthi | 26.20% | -20.60% |
| EPS growthi | +26.20% | -20.60% |
| FCF margini | +13.89% | +11.44% |
| Operating margini | 54.22% | 42.54% |
| Profit margini | 33.53% | 35.35% |
| ROIC proxyi | 102.29% | 59.81% |
| Return on equityi | 102.29% | 59.81% |
| Dividend yieldi | 0.59% | 4.15% |
| Payout ratioi | 21.69% | 44.46% |
| Dividend growth streaki | No increase yet | 7 yrs |
| Betai | 0.51 | 0.34 |
| Debt/equityi | 162.07 | 63.33 |
| Current ratioi | 1.35 | 0.87 |
| Quick ratioi | 0.68 | 0.64 |
Over the past year, LLY and NVO have moved weakly in the same direction (correlation of 0.23), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | LLY | NVO |
|---|---|---|---|
| 1Y | Growthi | +54.30% | -31.17% |
| CAGRi | +54.46% | -31.26% | |
| Volatilityi | 35.82% | 46.37% | |
| Sharpe ratioi | 1.27 | -0.67 | |
| Sortino ratioi | 2.16 | -0.89 | |
| Max drawdowni | 23.31% | 43.67% | |
| Current drawdowni | 9.02% | 34.69% | |
| Avg drawdowni | 6.61% | 23.04% | |
| Ulcer Indexi | 8.63% | 25.55% | |
| Max daily dropi | 7.79% | 16.43% | |
| Max wkly dropi | 8.60% | 26.95% | |
| 5Y | Growthi | +420.58% | -12.29% |
| CAGRi | +39.12% | -2.59% | |
| Volatilityi | 32.76% | 39.06% | |
| Sharpe ratioi | 1.04 | 0.02 | |
| Sortino ratioi | 1.60 | 0.02 | |
| Max drawdowni | 34.48% | 74.70% | |
| Current drawdowni | 9.02% | 70.66% | |
| Avg drawdowni | 7.41% | 25.53% | |
| Ulcer Indexi | 10.21% | 36.61% | |
| Max daily dropi | 14.14% | 21.83% | |
| Max wkly dropi | 17.93% | 33.45% | |
| 10Y | Growthi | +1564.30% | +118.38% |
| CAGRi | +32.49% | +8.12% | |
| Volatilityi | 30.55% | 32.81% | |
| Sharpe ratioi | 0.93 | 0.27 | |
| Sortino ratioi | 1.44 | 0.37 | |
| Max drawdowni | 34.48% | 74.70% | |
| Current drawdowni | 9.02% | 70.66% | |
| Avg drawdowni | 6.97% | 17.40% | |
| Ulcer Indexi | 9.34% | 27.29% | |
| Max daily dropi | 14.14% | 21.83% | |
| Max wkly dropi | 17.93% | 33.45% |
| Category | LLY | NVO |
|---|---|---|
| Company | LLY | NVO |
| Sector | Healthcare | N/A |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. | Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.